CINP World Congress - Collegium Int'l Neuro-Psycopharmacologieum
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to CINP World Congress - Collegium Int'l Neuro-Psycopharmacologieum — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
CINP World Congress – Collegium Int’l Neuro-Psycopharmacologieum (CINP2026)
Event overview
The 37th World Congress of Neuropsychopharmacology (CINP2026) is scheduled to be held in Glasgow, UK at the Scottish Event Campus, from Friday June 26th to Monday June 29th, 2026. The congress theme is “Advancing Brain Health Together”.
This is a scientific and medical conference centered on neuropsychopharmacology, bringing together researchers and clinicians focused on psychiatric and neurological disorders, with a strong translational orientation toward therapies, biomarkers, and brain-health outcomes.
Theme and why it matters for the audience
The congress theme, Advancing Brain Health Together, is reflected in the congress narrative on the event website: it positions CINP as a forum where academic research, clinical investigation, and industry innovation align around brain-health advances.
The event’s context highlights the UK’s and specifically Glasgow’s research strength in neuroscience and neuropsychiatric science, including initiatives that span neuroprotection, neuroimaging and genetics for psychiatric disorders, and early clinical mechanistic studies for novel interventions.
1️⃣ Who attends (BUYERS / ATTENDEES)
CINP2026 is not a consumer or general medical fair; it is a specialized scientific/medical congress. In practice, it attracts attendee groups that function as “buyers” of research, programs, scientific services, clinical trial support, and innovation partnerships—especially those responsible for medical/clinical strategy, evidence generation, and translational development.
Primary attendee groups
- Clinical investigators and physicians working in psychiatry, neuropsychiatry, and related neurological specialties.
- Academic researchers in neuroscience, neuroimaging, neurogenetics, psychopharmacology, and neurobiological mechanisms of disease.
- Translational medicine and clinical development professionals affiliated with biopharma and research-oriented organizations.
- Medical affairs and clinical strategy teams that track emerging evidence and competitor activity.
- Biomarker and diagnostics stakeholders focused on imaging-genetic approaches, risk prediction, and treatment response markers.
- Industry exhibitors and sponsors tied to neurotherapeutics, CNS drug discovery, and supportive ecosystem services.
- Representatives from research institutes and university centers seeking collaboration and partnership.
- Methodology and study-support stakeholders connected to clinical trial design, evidence synthesis, and scientific platforms (where applicable for congress programming and exhibitor activity).
Buyer-focused takeaway
For buyer alignment, the strongest “decision-maker” attendee profiles typically sit within CNS/psychiatry therapeutic areas and within organizations accountable for clinical development strategy, medical evidence planning, research collaborations, and brain-health innovation.
2️⃣ Where the show is happening + attendee geographic origin
Show location (official)
Scottish Event Campus, Glasgow, UK
Attendee geographic origin (reliable directional estimate)
Based on the congress being a World Congress in the field of neuropsychopharmacology, the attendee mix is expected to be international—commonly drawing from North America, Europe, and other regions with active CNS research and clinical programs.
However, the provided official text does not list a quantified geographic breakdown by country/region. Where exact proportions are not provided, we keep the analysis qualitative rather than inventing numbers.
Best geographic targeting approach
- United Kingdom and Ireland (host-country depth, plus the text’s emphasis on UK influence and research initiatives).
- Europe (strong concentration of neuropsychiatric research networks and cross-border clinical trials).
- North America (major pharma/biotech CNS pipelines and a large research community).
- Global (Asia-Pacific and other regions participate in global neuroscience and CNS innovation events, though exact origin shares are not specified in the supplied official content).
3️⃣ Audience reach (Local / National / Global)
CINP2026 should be categorized primarily as global reach within the neuropsychopharmacology and CNS ecosystem. The event title explicitly indicates a World Congress and the theme emphasizes international collaboration (“Advancing Brain Health Together”).
While the venue is in Glasgow (making local participation naturally strong), the congress’s scientific scope and world congress positioning indicate that the core value is typically international visibility and scientific exchange.
4️⃣ Sample buyer company names (BUYERS ONLY) + Websites
The event attracts organizations involved in neuropsychopharmacology, including CNS-focused biopharma, psychiatry therapeutics companies, and research-intensive medical science enterprises. Below is a curated buyer-only sample list aligned to that typical audience profile.
Note: This sample is built to match the expected congress buying interest (CNS/psychiatry/brain health strategy and clinical research). The most accurate “best fit buyers” for our client depends on the client’s exact product category and target job function(s).
| Priority | Company | Website | Best Title to Target | Why this is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Lundbeck | https://www.lundbeck.com | VP, Translational Medicine (CNS) / Head of CNS Clinical Development | Strong CNS/psychiatry focus; likely involved in evidence generation and clinical strategy aligned with neuropsychopharmacology congress themes. |
| 2 | Otsuka | https://www.otsuka-us.com | Global Program Director, Psychiatry / Medical Director, CNS | Psychiatry and neuropsychiatric programs align closely with the field; congress is a place for mechanism-to-clinic updates. |
| 3 | Janssen (Johnson & Johnson) | https://www.janssen.com | Vice President, Clinical Development (Psychiatry/CNS) / Therapeutic Area Lead | Major psychiatric portfolio presence; congress attendance supports medical strategy and collaboration across brain-health research. |
| 4 | Pfizer | https://www.pfizer.com | Senior Director, Neuropsychiatry Clinical Development / Medical Affairs Director, CNS | Neuroscience and psychiatry research relevance; strong probability of stakeholder attendance around CNS pipeline learnings. |
| 5 | Roche | https://www.roche.com | Head of CNS Translational Research / Director, Neuroscience Innovation | R&D platform and clinical translation interests make it a relevant “brain-health” buyer profile for specialized congress engagement. |
| 6 | Novartis | https://www.novartis.com | Global Clinical Development Lead, CNS / Medical Director, Psychiatry | Large-scale CNS development capabilities; typically engaged with mechanism-based research communities. |
| 7 | AstraZeneca | https://www.astrazeneca.com | Therapeutic Area Strategy Director, Psychiatry/CNS / Clinical Development Director | Neuroscience program interest commonly extends to psychiatry and neurobiology-focused medical congresses. |
| 8 | Biogen | https://www.biogen.com | Director, Neurology/CNS Clinical Strategy / Translational Medicine Lead | Brain-focused R&D and clinical strategy alignment with neuropsychopharmacology and neurotherapeutics themes. |
| 9 | Sanofi | https://www.sanofi.com | Global Program Lead, CNS / Director, Clinical Trials (Neuroscience) | Neuroscience and therapeutic innovation relevance; congress participation supports pipeline and collaboration visibility. |
| 10 | Merck (MSD) | https://www.merck.com | Senior Director, CNS/Neuroscience Research / Clinical Development Director | Fit for organizations with neuroscience research priorities and translational medicine pipelines. |
| 11 | Takeda | https://www.takeda.com | VP, Clinical Development (CNS) / Therapeutic Area Lead, Psychiatry | Psychiatry and CNS program presence historically makes it a relevant target for world congress engagement. |
| 12 | AbbVie | https://www.abbvie.com | Director, Neuroinflammation/CNS Development / Medical Affairs Director | Where relevant programs touch brain mechanisms and neurotherapeutics, the congress theme supports strong strategic interest. |
| 13 | Bristol Myers Squibb | https://www.bms.com | Global Clinical Development Lead, CNS / Medical Director, Psychiatry | Psychiatry-related development and evidence planning teams typically monitor this type of high-specialty congress. |
| 14 | GSK | https://www.gsk.com | Director, Neuroscience Research / Head of Clinical Trials, Psychiatry | Neuroscience and psychiatry strategic roles often align with neuropsychopharmacology communities. |
| 15 | Eli Lilly and Company | https://www.lilly.com | Director, Neuroscience Translational Science / Clinical Development Director, Psychiatry | CNS translational leadership roles commonly seek high-signal scientific interactions for mechanism-to-outcomes programs. |
| 16 | Teva Pharmaceuticals | https://www.tevapharm.com | Head of Psychiatry Clinical Development / Medical Director, CNS | Psychiatry portfolio and neuroscience engagement typically correspond to attendee needs at specialized neuropharmacology congresses. |
| 17 | Merz Pharma | https://www.merz.com | Clinical Development Lead, CNS/Neurology / Medical Affairs Director | Neuroscience-related development teams can align with brain-health and mechanism-driven conference programming. |
| 18 | ICON plc | https://www.iconplc.com | Director, Clinical Operations (CNS) / Senior Program Director, Trials | Clinical trial services organizations can be relevant “buyers” for trial design/support ecosystems supporting CNS research. |
| 19 | IQVIA | https://www.iqvia.com | Director, Real-World Evidence (Neuroscience) / Strategy Director, Healthcare Insights | Evidence, analytics, and program strategy roles often match congress environments where outcomes and biomarkers are discussed. |
| 20 | Labcorp | https://www.labcorp.com | Director, Clinical Trials Laboratory Services / Business Unit Manager, Central Labs (Neuroscience) | Where clinical study support is relevant, laboratory and biomarker testing vendors become natural stakeholders in CNS congress ecosystems. |
Top “first outreach” set (if we prioritize best-fit archetypes)
We recommend beginning with: Lundbeck, Otsuka, Janssen, Pfizer, Roche. These represent strong probability of relevance to neuropsychopharmacology and brain-health strategy roles.
5️⃣ Job profiles, industries & event type
Job profiles to target (high-confidence buyer roles)
- Head/VP/Director, Clinical Development (CNS/Psychiatry)
- VP/Director, Translational Medicine (Neuroscience)
- Medical Director, Psychiatry/CNS
- Therapeutic Area Lead, Neuropsychiatry
- Program Director, Psychiatry/CNS
- Director, Neuroscience Research
- Biomarker/Imaging Strategy Lead (where imaging-genetics collaborations are relevant)
- Clinical Operations Lead (CNS trial execution stakeholders)
- Evidence Generation / Medical Affairs Strategy
- Research Collaboration / Partnering Lead (university and institute collaboration roles)
Event type
World Congress / Medical & scientific conference focused on neuropsychopharmacology, with education, scientific sessions, and cross-stakeholder networking tied to brain-health advancement.
Industries aligned to the attendee community
- Pharmaceuticals
- Biotechnology
- Research
- Hospital & Health Care
- Mental Health Care
- Medical Practice
- Medical Devices (when relevant to diagnostics/monitoring, if exhibitor presence includes this)
These industry mappings follow the typical alignment for a neuropsychopharmacology congress audience.
6️⃣ Estimated attendance (expected total footfall)
The official content provided does not include an estimated total attendance figure. Since we must not invent numbers, we recommend capturing attendance estimates from the congress’s exhibitor/sponsorship materials (such as the floorplan, sponsorship prospectus, or exhibitor list pages) if available in your research workflow.
What we can say reliably: the event is a four-day world congress, which typically implies multi-track scientific programming and a meaningful exhibitor and sponsor presence, but the exact footfall remains unspecified in the provided text.
7️⃣ Key focus areas & buyer engagement
Likely scientific and industry focus areas
- Brain-health and neurodegenerative mechanisms (e.g., neuroprotective strategies and translational outcomes)
- Psychiatric disorders and neurobiological underpinnings (mechanisms related to schizophrenia, bipolar disorder, and related conditions)
- Neuroimaging and genetic approaches to identify biomarkers and support more targeted therapies
- Clinical and mechanistic trials that connect intervention hypotheses with brain mechanisms
- Therapeutics innovation in neurotherapeutics, including anti-inflammatory and CNS-targeted strategies
- Collaborative research alignment across partner and peer organizations around the congress theme
- Cross-stakeholder knowledge exchange between academia, clinical centers, and industry development teams
How we should position buyer engagement
For buyer-facing engagement, the strongest approach is to align to the roles that influence how evidence, biomarkers, trials, and partnerships progress in CNS and psychiatry:
- Position messaging around translational relevance (“mechanism-to-clinic” and brain-health outcomes).
- Target stakeholders who shape CNS clinical development priorities and evidence generation strategies.
- Where appropriate, tailor engagement around biomarkers (imaging/genetics), trial execution, and scientific partnering.
8️⃣ Client-product fit: Best buyers based on our client’s requirements
To identify the best buyers with the highest relevance to our client’s needs, we need the client’s product positioning from their website. We will review the client website and then map buyer roles and company types to the congress attendee ecosystem accordingly.
Please share
- Client website URL
- What the client sells (1–2 sentences)
- Buyer “must-have” job functions (e.g., clinical development, medical affairs, research, diagnostics, trial operations)
- Target regions (if any)
- Any compliance constraints (if applicable)
What we will deliver once we have the client website
- A refined “top buyer list” (company + best title targets) tailored to the client’s category (e.g., CNS therapeutics ecosystem, research services, diagnostics/biomarkers, clinical trial support, or evidence generation).
- A ranked mapping of which buyer segments to prioritize by relevance to neuropsychopharmacology and brain-health work.
- A suggested outreach angle that matches the congress theme “Advancing Brain Health Together.”
Action needed from you: share the client website and we will complete this section with a concrete “best buyers for our client” outcome.
9️⃣ Suggested industry targeting (aligned to Apollo-style industry list)
Below are the most relevant industry filters to use (from the provided Apollo-style industry list) for CINP2026 audience targeting. We focus on industries that align with the neuropsychopharmacology/brain-health ecosystem.
- Pharmaceuticals
- Biotechnology
- Research
- Hospital & Health Care
- Medical Practice
- Mental Health Care
- Medical Devices (when diagnostics/monitoring is part of the exhibitor ecosystem)
- Events Services (optional, only if we are targeting scientific event ecosystem vendors)
Additionally, we recommend layering in keyword-based targeting on company descriptions for “CNS,” “neuropsychiatry,” “neuropsychopharmacology,” “psychiatry,” “brain health,” “translational medicine,” and “biomarkers/imaging.”
Quick facts (from official event information)
- Congress: 37th World Congress of Neuropsychopharmacology
- Dates: June 26–29, 2026
- Venue: Scottish Event Campus
- City/Country: Glasgow, UK
- Theme: Advancing Brain Health Together
Data sheet
CINP World Congress - Collegium Int'l Neuro-Psycopharmacologieum – Event Attendee & Buyer Profile Analysis
Event Date: June 26, 2026 – June 29, 2026
Location: Glasgow, Scotland, United Kingdom
Event Status: Completed
Research Date: June 30, 2026
Event Overview
| Field | Details |
|---|---|
| Event Name | 37th World Congress of Neuropsychopharmacology (CINP 2026) |
| Event Date | June 26, 2026 – June 29, 2026 |
| Event Status | Completed |
| Venue | Scottish Event Campus |
| City | Glasgow |
| State / Region | Scotland |
| Country | United Kingdom |
| Organizer | Collegium Internationale Neuro-Psychopharmacologicum (CINP) |
| Official Event Website | cinp2026.org |
| Event Type | International medical congress / scientific conference / association meeting |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Wellness, Health & Fitness |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | Estimated 1,500–3,500 delegates, speakers, exhibitors, sponsors, and institutional visitors. |
| Attendance Data Reliability | Estimated. Attendance figure not publicly confirmed by the organizer. |
| Main Purpose of Event | Advance brain health and neuropsychopharmacology research through scientific sessions, keynote presentations, abstract submissions, sponsored symposia, networking, exhibitions, and collaboration among clinicians, researchers, institutions, and industry. |
About the Event
CINP 2026 is the 37th World Congress of Neuropsychopharmacology, held in Glasgow at the Scottish Event Campus. The congress brings together the global neuropsychopharmacology community to share research on brain health, psychiatric disorders, neurological innovation, and therapeutic development. The official program structure indicates a strong scientific and educational focus, with abstracts, keynote speakers, symposia, presentations, sponsorship, exhibitors, and a congress app supporting attendee engagement.
This event matters because it sits at the intersection of academic research, clinical medicine, pharmaceutical development, and translational neuroscience. It is relevant for organizations involved in drug discovery, mental health treatment, neurodegenerative disease, CNS therapeutics, research tools, diagnostics, and institutional collaboration. For B2B outreach, it offers a concentrated audience of decision-makers and influencers from universities, hospitals, pharma, biotech, and research-oriented associations.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical researchers and principal investigators | Universities, teaching hospitals, research institutes | Influence on study design, trial partnerships, and research procurement | Relevant for scientific software, lab tools, biomarkers, diagnostics, and clinical trial support. |
| Psychiatrists and neurologists | Hospitals, specialty clinics, healthcare systems | Clinical adoption, protocol influence, referral and treatment decisions | Relevant for therapeutics, digital health, diagnostic tools, and education services. |
| Pharma R&D leaders | Pharmaceutical and biotech companies | Pipeline strategy, partnerships, licensing, and vendor evaluation | High relevance for CROs, preclinical services, assay providers, and CNS-focused vendors. |
| Translational science and discovery teams | Biotech firms, academic medical centers | Research collaboration and technology selection | Relevant for research platforms, data analytics, imaging, and experimental models. |
| Clinical trial and operations leaders | Sponsors, CROs, hospitals, research networks | Vendor selection and operational execution | Relevant for trial management tools, regulatory support, patient recruitment, and site services. |
| Medical affairs and evidence generation teams | Pharma and medtech organizations | Scientific engagement, congress strategy, publication planning | Relevant for medical communications, congress sponsorship, and evidence services. |
| Academic department leaders | Universities, research hospitals | Budget influence, collaboration approval, research direction | Relevant for institutional partnerships, grants, education platforms, and technology licensing. |
| Association and society leaders | Professional societies, advocacy groups | Partnerships, sponsorships, and program development | Relevant for membership services, event technology, and educational products. |
| Industry sponsors and exhibitors | Pharma, biotech, research tools, diagnostics | Budget holders for event marketing and lead generation | Relevant for stand builds, sponsorship packages, attendee data, and B2B lead capture. |
| Media and scientific communications | Medical media, publishers, journals | Content amplification and reputation building | Relevant for publishing, PR, medical writing, and research dissemination. |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Glasgow | Local and regional delegates from universities, hospitals, and life science organizations | Medium | Major Scottish academic and healthcare hub with strong conference accessibility. |
| Host region: Scotland | Scottish universities, NHS stakeholders, research institutes, and biotech firms | Medium | Strong concentration of medical research and public health stakeholders. |
| United Kingdom | National attendee base from England, Scotland, Wales, and Northern Ireland | High | Official content explicitly notes the congress returns to the UK after more than 25 years. |
| Nearby business hubs | Edinburgh, London, Manchester, Cambridge, Oxford, Newcastle, Leeds | High | High-value clusters for pharma, biotech, hospitals, and universities. |
| Europe | Delegates from major EU research and pharma markets | High | Likely strong representation due to scientific and association nature of event. |
| North America | US and Canadian researchers, clinicians, pharma sponsors | Medium | Relevant for global congresses in neuropsychopharmacology and CNS research. |
| Global research markets | International academic, clinical, and industry participants | High | International scientific congress with broad research relevance and sponsorship appeal. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The congress is an international scientific meeting with worldwide relevance to neuroscience, psychiatry, pharmacology, and CNS drug development. |
| Secondary Reach | Strong UK and European draw | Glasgow location and scientific focus make it especially relevant to UK, EU, and transatlantic research and pharma networks. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Imperial College London | Academic / research institution | Referenced in the official congress content as a current UK research contributor in neuroscience and mental health. | imperial.ac.uk | Professor, PI, Research Director, Department Head | Confirmed speaker / research organization |
| University of Edinburgh | Academic / research institution | Named by the official congress site for psychiatric disorder research and neuroimaging-genetics studies. | ed.ac.uk | Professor, Clinical Research Lead, Institute Director | Confirmed speaker / research organization |
| University of Sheffield | Academic / research institution | Mentioned in the official congress text for therapeutics development related to stroke and spinal cord injury. | sheffield.ac.uk | Research Director, Principal Investigator, Innovation Lead | Confirmed speaker / research organization |
| Scottish Event Campus | Venue / event infrastructure | Official congress venue; relevant for event-tech, audiovisual, logistics, and hospitality suppliers. | sec.co.uk | Venue Director, Operations Manager, Event Services Lead | Confirmed venue organization |
| Collegium Internationale Neuro-Psychopharmacologicum (CINP) | Association / organizer | Organizer and primary scientific network for global neuropsychopharmacology stakeholders. | cinp.org | Association Executive, Program Director, Sponsorship Lead | Confirmed organizer |
| National Health Service (NHS) | Public healthcare system | Large clinical stakeholder group for psychiatry, neurology, and treatment pathways. | nhs.uk | Clinical Director, Procurement Lead, Service Manager | Strong Market Fit, Attendance Not Confirmed |
| University of Oxford | Academic / research institution | Major UK neuroscience and psychiatric research buyer profile for congress-related technology and partnerships. | ox.ac.uk | Professor, Head of Department, Research Manager | Strong Market Fit, Attendance Not Confirmed |
| University College London | Academic / research institution | High-fit institution for brain health, psychiatry, and translational neuroscience procurement. | ucl.ac.uk | Principal Investigator, Lab Director, Research Administrator | Strong Market Fit, Attendance Not Confirmed |
| King’s College London | Academic / research institution | Major mental health and neuroscience research organization aligned with conference themes. | kcl.ac.uk | Professor, Clinical Research Lead, Program Manager | Strong Market Fit, Attendance Not Confirmed |
| University of Cambridge | Academic / research institution | Relevant buyer profile for CNS research collaborations, tools, and scientific services. | cam.ac.uk | Department Chair, PI, Research Operations Manager | Strong Market Fit, Attendance Not Confirmed |
| Roche | Pharmaceutical / biotech | Global pharma buyer profile for CNS therapeutics, evidence generation, and congress sponsorship. | roche.com | Medical Affairs Director, R&D Lead, Portfolio Manager | Strong Market Fit, Attendance Not Confirmed |
| Novartis | Pharmaceutical / biotech | Potential buyer for neuroscience-related research services, sponsorship, and partnership opportunities. | novartis.com | Clinical Development Lead, Scientific Director, Partnership Manager | Strong Market Fit, Attendance Not Confirmed |
| Pfizer | Pharmaceutical / biotech | High-value pharma target for CNS, psychiatry, and medical education engagement. | pfizer.com | Medical Affairs, R&D, External Innovation Lead | Strong Market Fit, Attendance Not Confirmed |
| Johnson & Johnson | Pharmaceutical / medical technology | Relevant for neuroscience research, clinical development, and congress sponsorship. | jnj.com | Scientific Director, Alliance Manager, Procurement Lead | Strong Market Fit, Attendance Not Confirmed |
| Eli Lilly and Company | Pharmaceutical / biotech | Important buyer profile for CNS therapies and evidence-based medical engagement. | lilly.com | Brand Lead, Clinical Strategy, Medical Affairs Director | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Medical Officer / Chief Scientific Officer | Executive / R&D | C-Level | Owns scientific direction, partnerships, and strategic research priorities. |
| 2 | VP Research & Development | R&D | VP | Influences external collaborations, vendor selection, and pipeline investment. |
| 3 | Medical Affairs Director | Medical Affairs | Director | Shapes congress engagement, publications, and scientific communications. |
| 4 | Director of Clinical Development | Clinical Development | Director | Evaluates trial strategy, evidence generation, and partner capabilities. |
| 5 | Principal Investigator | Research | Senior / Lead | Key influence on academic collaborations, grants, and study procurement. |
| 6 | Department Chair / Division Head | Academic Medicine | Senior Leadership | Controls departmental budgets and collaboration approvals. |
| 7 | Research Program Manager | Research Administration | Manager | Coordinates projects, suppliers, and conference-related sourcing needs. |
| 8 | Clinical Research Manager | Clinical Research | Manager | Manages study operations and service provider evaluation. |
| 9 | Procurement Manager | Procurement | Manager | Useful for supplier selection across research, facilities, and event purchases. |
| 10 | Partnerships Director | Business Development / Alliances | Director | Looks for sponsorship, licensing, and strategic collaboration opportunities. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Core industry for CNS drug development, medical affairs, and research collaboration. | Target sponsors, R&D, medical affairs, and clinical development leaders. |
| 2 | Biotechnology | Highly aligned with neuroscience innovation, biomarker work, and translational research. | Target founders, scientific leaders, and business development teams. |
| 3 | Hospital & Health Care | Important source of clinicians, researchers, and decision-makers in psychiatry and neurology. | Target clinical directors, department heads, and research leads. |
| 4 | Higher Education | Major attendee base from universities and academic medical centers. | Target professors, lab heads, research office, and grant teams. |
| 5 | Research | Directly relevant to the congress’s scientific and translational mission. | Target principal investigators, research directors, and study teams. |
| 6 | Medical Devices | Relevant for neurodiagnostics, monitoring, imaging, and adjacent clinical technologies. | Target product managers and clinical application specialists. |
| 7 | Information Technology & Services | Relevant for congress apps, digital health, data platforms, and research informatics. | Target digital health, data, and scientific software buyers. |
| 8 | Biotechnology | Supports translational science, diagnostics, and therapeutic innovation. | Target partnerships, pipeline, and licensing teams. |
| 9 | Medical Practice | Includes specialist clinicians attending for professional education and adoption decisions. | Target specialty physicians and service line leads. |
| 10 | Management Consulting | Relevant for strategy, market access, and life sciences advisory services. | Target consultants supporting pharma and healthcare clients. |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 1,500–3,500 | Estimated | Based on scale of a global specialty medical congress with exhibitions, sponsorship, abstracts, and keynote program. | Attendance figure not publicly confirmed by the organizer. |
| Exhibitor count | Not publicly confirmed | Confirmed pages exist, count not shown | Official website includes “List of Exhibitors” and sponsorship pages. | Could not verify count from provided official text. |
| Buyer count | Not publicly confirmed | Not confirmed | No official buyer list in provided source text. | Buyer audiences likely embedded across clinicians, researchers, pharma, and institutional leaders. |
| Speaker count | Not publicly confirmed | Not confirmed | Official site lists keynote speakers and scientific committee pages. | Specific speaker volume not visible in the provided source extract. |
| Sponsor count | Not publicly confirmed | Not confirmed | Official site includes sponsorship and supporters pages. | Specific sponsor volume not visible in the provided source extract. |
| Historical attendance | Not provided in source extract | Unavailable | Official site content supplied does not show prior-year attendance metrics. | Use organizer materials or post-event report if available. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Neuroscience research | Scientific collaboration, data, and tooling | Connect through abstracts, poster sessions, and research meetings | Research services, analytics, lab platforms, imaging |
| Psychiatry and mental health | Clinical evidence and treatment innovation | Position therapies, studies, and clinical support solutions | Pharma, diagnostics, digital mental health, education |
| CNS drug development | Pipeline acceleration and trial execution | Engage medical affairs and R&D leaders at symposia and sponsorships | CROs, trial services, regulatory, biomarker providers |
| Translational medicine | Bridge discovery to clinical adoption | Highlight proof-of-concept and partnership pathways | Biotech platforms, assay development, data services |
| Scientific communications | Congress visibility and publication support | Target sponsors, exhibitors, and medical communications teams | PR, medical writing, publication planning |
| Congress technology | App, registration, and attendee engagement | Reach event organizers and exhibitors needing digital tools | Event apps, CRM, lead capture, networking platforms |
| Academic partnerships | Funding, collaboration, and talent exchange | Use networking and committee sessions to build relationships | Grants support, institutional partnerships, sponsorship |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event attracts researchers, clinicians, pharma, and academic decision-makers aligned to neuropsychopharmacology. |
| Decision-maker availability | High | Scientific congresses typically bring senior experts, PIs, department heads, and sponsor-facing leaders. |
| Data collection potential | Medium | Useful exhibitor and sponsor data is present, but a public attendee list was not provided in the source extract. |
| Apollo targeting potential | Very High | Strong fit for pharma, biotech, healthcare, higher education, and research filters. |
| Geographic targeting potential | High | Clear UK, European, and global scientific audience with Glasgow as a strong research hub. |
| Best outreach approach | High-touch, account-based, scientific relevance | Use congress content, session themes, and research interests for personalized outreach. |
| Overall lead quality | High | Strong B2B value for attendee intelligence, sponsorship prospecting, and research-sector lead generation. |
| Best use case | Scientific B2B prospecting and event sponsorship intelligence | Well suited for attendee list building, pharma outreach, and academic account targeting. |
| Limitations / risks | Moderate | Current-year public attendee list was not visible in the provided source text; some buyer segments are inferred from event fit rather than confirmed participation. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals; Biotechnology; Hospital & Health Care; Higher Education; Research; Medical Devices; Information Technology & Services; Medical Practice; Management Consulting | Prioritize the most relevant buyer ecosystems for neuropsychopharmacology and CNS research. |
| Departments | R&D; Medical Affairs; Clinical Development; Research; Procurement; Partnerships; Business Development; Information Technology | Reach the teams most likely to evaluate vendors, partners, and event sponsorship opportunities. |
| Seniority | C-Level; VP; Director; Head; Manager; Professor / Faculty Lead | Target budget holders, strategic influencers, and scientific decision-makers. |
| Job titles | Chief Scientific Officer; Chief Medical Officer; VP R&D; Medical Affairs Director; Clinical Development Director; Principal Investigator; Professor; Department Chair; Research Director; Procurement Manager; Partnerships Director | High-intent titles for scientific engagement, procurement, and partnership development. |
| Geography | United Kingdom; Ireland; Western Europe; Nordics; United States; Canada; select global research hubs | Match the likely attendee footprint for an international congress hosted in Glasgow. |
| Employee size | 201–500; 501–1,000; 1,001–5,000; 5,001–10,000; 10,000+ | Best fit for established institutions, hospital systems, and pharma organizations. |
| Keywords | neuropsychopharmacology, psychiatry, neuroscience, CNS, brain health, mental health, clinical development, translational research, biomarkers, drug discovery | Refine search results around congress themes and buying intent. |
| Company type | Public companies; universities; hospitals; research institutes; pharma sponsors; biotech firms | Focus on organizations most likely to attend, sponsor, or buy from the event ecosystem. |
| Revenue range | $10M+ for commercial targets; broader for academic/public institutions | Prioritize organizations with procurement capacity and conference sponsorship budgets. |
| Technologies | Clinical trial management, research informatics, digital health, medical communications, event apps, data platforms | Useful when targeting solution providers and technology-buying teams within attendee organizations. |
Suggested Apollo Search Logic: Use combinations such as (Pharmaceuticals OR Biotechnology OR Hospital & Health Care OR Higher Education OR Research) AND (R&D OR Medical Affairs OR Clinical Development OR Research OR Procurement) AND (Director OR VP OR Head OR Professor OR Manager) with keywords like neuroscience, psychiatry, CNS, brain health, and clinical development.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| CINP 2026 Official Website | Official organizer website | Event title, dates, Glasgow location, Scottish Event Campus venue, scientific theme, program structure, exhibitors page, sponsorship pages. | Very High |
| CINP 2026 homepage copy provided in prompt | Primary source extract | Confirmed June 26–29, 2026 timing, Glasgow venue, and congress focus on brain health and neuropsychopharmacology. | Very High |
| Scottish Event Campus | Venue website | Venue identity and host city context for the congress location. | High |
| CINP Association Website | Organizer / association website | Organizer identity and association context for the World Congress of Neuropsychopharmacology. | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to CINP World Congress - Collegium Int'l Neuro-Psycopharmacologieum — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds